BACKGROUND: We have postulated that metabolic oxidation could be the source of signs and symptoms of hyperthyroidism. The present study was designed to evaluate urinary malondialdehyde levels in Graves' disease and compare this oxidative stress biomarker with the clinical evolution of patients suffering this illness. METHODS: We evaluated the concentration of urinary and serum malondialdehyde (MDA) in 36 patients with Graves' disease. Patients were treated with the antithyroid drug methimazole (MMI; Group A) or antioxidant mixture (200 mg vitamin E, 3 mg beta-carotene, 250 mg vitamin C, 1 mg Cu, 7.5 mg Zn, 1.5 mg Mn, and 15 microg Se; Group B). RESULTS: MDA concentrations were higher in hyperthyroid patients compared to euthyroid controls, and a positive correlation was observed between serum and urinary MDA levels. Group A decreased urinary MDA to control values. There was a positive correlation between the clinical score and the heart rate of patients with urinary MDA before and during the treatment with MMI (Group A). Similar results were observed after treatment with the antioxidant mixture. CONCLUSIONS: Urinary MDA might be a good parameter in the follow-up of patients during MMI treatment. We proposed that oxidative stress correlates with signs and symptoms of hyperthyroidism.
BACKGROUND: We have postulated that metabolic oxidation could be the source of signs and symptoms of hyperthyroidism. The present study was designed to evaluate urinary malondialdehyde levels in Graves' disease and compare this oxidative stress biomarker with the clinical evolution of patients suffering this illness. METHODS: We evaluated the concentration of urinary and serum malondialdehyde (MDA) in 36 patients with Graves' disease. Patients were treated with the antithyroid drug methimazole (MMI; Group A) or antioxidant mixture (200 mg vitamin E, 3 mg beta-carotene, 250 mg vitamin C, 1 mg Cu, 7.5 mg Zn, 1.5 mg Mn, and 15 microg Se; Group B). RESULTS: MDA concentrations were higher in hyperthyroidpatients compared to euthyroid controls, and a positive correlation was observed between serum and urinary MDA levels. Group A decreased urinary MDA to control values. There was a positive correlation between the clinical score and the heart rate of patients with urinary MDA before and during the treatment with MMI (Group A). Similar results were observed after treatment with the antioxidant mixture. CONCLUSIONS: Urinary MDA might be a good parameter in the follow-up of patients during MMI treatment. We proposed that oxidative stress correlates with signs and symptoms of hyperthyroidism.
Authors: M Leo; L Bartalena; G Rotondo Dottore; E Piantanida; P Premoli; I Ionni; M Di Cera; E Masiello; L Sassi; M L Tanda; F Latrofa; P Vitti; C Marcocci; M Marinò Journal: J Endocrinol Invest Date: 2016-10-12 Impact factor: 4.256
Authors: P Calzadilla; M Gómez-Serrano; E García-Santos; A Schiappacasse; Y Abalde; J C Calvo; B Peral; L N Guerra Journal: Redox Rep Date: 2013 Impact factor: 4.412
Authors: Marziyeh Salami; Ahmad Reza Bandegi; Hamid Reza Sameni; Abbas Ali Vafaei; Abbas Pakdel Journal: Neurochem Res Date: 2019-08-14 Impact factor: 3.996
Authors: Pablo Calzadilla; Daiana Sapochnik; Soledad Cosentino; Virginia Diz; Lelia Dicelio; Juan Carlos Calvo; Liliana N Guerra Journal: Int J Mol Sci Date: 2011-10-19 Impact factor: 5.923